Measured Wealth Private Client Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Measured Wealth Private Client Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.13M	Buy	+45,038	New	+$6.09M	1.72%	13
2018 Q4	–	Sell	-13	Closed	-$1K	–	722
2018 Q3	$1K	Buy	+13	New	+$1.26K	﹤0.01%	817

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Measured Wealth Private Client Group's XBI Position: Q2 2026 in Review

Measured Wealth Private Client Group opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 45,038 shares worth $7.13M. The stake represents 1.72% of the portfolio and ranks #13 among its holdings. This is a return to the name: Measured Wealth Private Client Group previously reported a position in XBI as recently as Q3 2018.

Measured Wealth Private Client Group first reported a position in XBI in Q3 2018 and has held it in 2 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Measured Wealth Private Client Group held 45,038 shares of State Street SPDR S&P Biotech ETF worth $7.13M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Measured Wealth Private Client Group position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 1.72% of Measured Wealth Private Client Group's portfolio in Q2 2026, its #13 holding.
Measured Wealth Private Client Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and has held it in 2 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2026, filed 10 Aug 2026.